Bruker (NASDAQ:BRKR) Downgraded to “Underweight” at Morgan Stanley

Bruker (NASDAQ:BRKR) was downgraded by research analysts at Morgan Stanley from an “equal weight” rating to an “underweight” rating in a note issued to investors on Thursday, September 20th, Marketbeat reports. They presently have a $32.00 price objective on the medical research company’s stock, up from their prior price objective of $31.00. Morgan Stanley’s price target would indicate a potential upside of 1.85% from the stock’s current price.

BRKR has been the topic of a number of other research reports. BidaskClub downgraded Bruker from a “buy” rating to a “hold” rating in a research report on Wednesday, June 20th. Zacks Investment Research downgraded Bruker from a “buy” rating to a “hold” rating in a research report on Friday, June 8th. Finally, ValuEngine downgraded Bruker from a “hold” rating to a “sell” rating in a research report on Wednesday, July 11th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $33.90.

Bruker stock traded up $0.66 during trading on Thursday, reaching $31.42. 482,184 shares of the company were exchanged, compared to its average volume of 607,620. Bruker has a 52-week low of $28.13 and a 52-week high of $36.53. The company has a market cap of $5.23 billion, a price-to-earnings ratio of 25.97, a PEG ratio of 2.11 and a beta of 1.34. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.27 and a current ratio of 2.22.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Thursday, August 2nd. The medical research company reported $0.25 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.25. Bruker had a return on equity of 27.03% and a net margin of 4.99%. The firm had revenue of $443.70 million for the quarter, compared to the consensus estimate of $436.10 million. During the same quarter last year, the business posted $0.23 earnings per share. The firm’s revenue was up 6.9% compared to the same quarter last year. On average, analysts predict that Bruker will post 1.38 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the stock. Millennium Management LLC raised its holdings in shares of Bruker by 15.2% in the 2nd quarter. Millennium Management LLC now owns 1,279,814 shares of the medical research company’s stock valued at $37,166,000 after buying an additional 168,597 shares during the period. Citadel Advisors LLC grew its stake in Bruker by 1,883.2% during the 2nd quarter. Citadel Advisors LLC now owns 761,988 shares of the medical research company’s stock worth $22,128,000 after purchasing an additional 723,566 shares in the last quarter. Allianz Asset Management GmbH grew its stake in Bruker by 215.1% during the 1st quarter. Allianz Asset Management GmbH now owns 955,177 shares of the medical research company’s stock worth $28,578,000 after purchasing an additional 652,032 shares in the last quarter. Swiss National Bank grew its stake in Bruker by 2.1% during the 1st quarter. Swiss National Bank now owns 192,700 shares of the medical research company’s stock worth $5,766,000 after purchasing an additional 3,900 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. grew its stake in Bruker by 7.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 667,122 shares of the medical research company’s stock worth $19,374,000 after purchasing an additional 47,728 shares in the last quarter. Hedge funds and other institutional investors own 65.61% of the company’s stock.

Bruker Company Profile

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

See Also: How Important is Technical Analysis of Stocks

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply